• The lancet oncology · Mar 2007

    Case Reports

    Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.

    • Simona Soverini, Giovanni Martinelli, Sabrina Colarossi, Alessandra Gnani, Michela Rondoni, Fausto Castagnetti, Stefania Paolini, Gianantonio Rosti, and Michele Baccarani.
    • Institute of Haematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, Italy. simona.soverini@tin.it
    • Lancet Oncol. 2007 Mar 1; 8 (3): 273-4.

    no abstract available

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,624,503 articles already indexed!

We guarantee your privacy. Your email address will not be shared.